OmniRayn
← All repurposing reports
S3 (505(b)(2)+Orphan) · Orphan-eligible

Sarcopenia

Known, approved drugs ranked as repurposing candidates for Sarcopenia — each scored for reversal of the disease expression signature, cytotoxicity-filtered, and prioritized by clinical maturity. Computational, pending wet-lab.

Preview. Candidate identities are shown below. The full ranking, quantified reversal scores, per-candidate mechanistic rationale, ClinicalTrials.gov whitespace detail, and structure-function intelligence are included with the dossier.

Top candidates preview

  1. 1ipratropiumApproved
  2. 2disopyramideApproved
  3. 3topiramateApproved
  4. 4verapamilApproved
  5. 5pentoxifyllineApproved
  6. 6benzylpenicillinApproved
  7. 7flufenamic acidApproved
  8. 8rofecoxibApproved

Full dossier — 149 cytotox-screened candidates

Quantified reversal ranking · mechanistic rationale · CT.gov whitespace · S3 (505(b)(2)+Orphan) regulatory framing · structure-function intelligence.

Acquire dossier — $3,950